All In Biotech

Drug Trial Radar · NCT02964403

COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis

Effect Observation Study of COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis

Last checked: Nov 20, 2026Latest source record: Nov 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 2,700 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

2,700

Planned (sponsor's estimate)

Start

Dec 2016

Primary completion

Feb 2018

Study completion Aug 2018

Sponsor

Lead sponsor
First Affiliated Hospital Xi'an Jiaotong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a "standard" method to prevent PEP. The mechanism of indomethacin is dependent on COX-2 inhibitor. According to data, we design the project. The purpose of this study is to determine whether COX-2 inhibitor is effective on control of Post-ERCP pancreatitis.

Conditions

  • Pancreatitis, Acute

Interventions

  • Cox-2Drug

  • IndomethacinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-ERCP PancreatitisTime frame: 30 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.